Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus S-1 for second-line advanced pancreatic cancer
ChiCTR1800016762Phase 3Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of Rivoceranib and tegafur in pancreatic cancer (PC) (2 arms), sponsored by Changzhou Second People's Hospital. Primary endpoint: Overall survival. Started Jan 2018; status: recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1800016762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016762.